Search

Your search keyword '"Lacour, Jean‐Philippe"' showing total 23 results
Start Over Author "Lacour, Jean‐Philippe" Publisher wiley
23 results on '"Lacour, Jean‐Philippe"'

2. Annular lipoatrophy of the ankle: Four new pediatric cases and a review of the literature

Author

Touhouche, Timila Assia, primary, Tournier, Emilie, additional, Lamant, Laurence, additional, Hardy, Juliette, additional, Taieb, Alain, additional, Labreze, Christine, additional, Cony, Marianne, additional, Lepreux, Sebastien, additional, Chiaverini, Christine, additional, Lacour, Jean Philippe, additional, Cardot‐Leccia, Nathalie, additional, Bedane, Christophe, additional, Assikar, Safae, additional, Charissoux, Aurélie, additional, and Mazereeuw‐Hautier, Juliette, additional

Published
2021
Full Text
View/download PDF

3. Propranolol pharmacokinetics in infants treated for Infantile Hemangiomas requiring systemic therapy: Modeling and dosing regimen recommendations

Author

Del Frari, Laurence, primary, Léauté-Labrèze, Christine, additional, Guibaud, Laurent, additional, Barbarot, Sébastien, additional, Lacour, Jean-Philippe, additional, Chaumont, Christine, additional, Delarue, Alain, additional, Voisard, Jean-Jacques, additional, and Brunner, Valérie, additional

Published
2018
Full Text
View/download PDF

5. Metformin monotherapy in melanoma: a pilot, open-label, prospective, and multicentric study indicates no benefit

Author

Montaudié, Henri, primary, Cerezo, Michael, additional, Bahadoran, Philippe, additional, Roger, Coralie, additional, Passeron, Thierry, additional, Machet, Laurent, additional, Arnault, Jean-Philippe, additional, Verneuil, Laurence, additional, Maubec, Eve, additional, Aubin, François, additional, Granel, Florence, additional, Giacchero, Damien, additional, Hofman, Véronique, additional, Lacour, Jean-Philippe, additional, Maryline, Allegra, additional, Ballotti, Robert, additional, and Rocchi, Stéphane, additional

Published
2017
Full Text
View/download PDF

7. High expression of TRF2, SOX10, and CD10 in circulating tumor microemboli detected in metastatic melanoma patients. A potential impact for the assessment of disease aggressiveness

Author

Long, Elodie, primary, Ilie, Marius, additional, Bence, Coraline, additional, Butori, Catherine, additional, Selva, Eric, additional, Lalvée, Salomé, additional, Bonnetaud, Christelle, additional, Poissonnet, Gilles, additional, Lacour, Jean-Philippe, additional, Bahadoran, Philippe, additional, Brest, Patrick, additional, Gilson, Eric, additional, Ballotti, Robert, additional, Hofman, Véronique, additional, and Hofman, Paul, additional

Published
2016
Full Text
View/download PDF

9. Fractionated bipolar radiofrequency and bipolar radiofrequency potentiated by infrared light for treating striae: A prospective randomized, comparative trial with objective evaluation

Author

Harmelin, Yona, primary, Boineau, Dominique, additional, Cardot‐Leccia, Nathalie, additional, Fontas, Eric, additional, Bahadoran, Philippe, additional, Becker, Anne‐lise, additional, Montaudié, Henri, additional, Castela, Emeline, additional, Perrin, Christophe, additional, Lacour, Jean‐Philippe, additional, and Passeron, Thierry, additional

Published
2016
Full Text
View/download PDF

12. Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?

Author

Passeron, Thierry, primary, Lacour, Jean-Philippe, additional, Allegra, Maryline, additional, Ségalen, Coralie, additional, Deville, Anne, additional, Thyss, Antoine, additional, Giacchero, Damien, additional, Ortonne, Jean-Paul, additional, Bertolotto, Corine, additional, Ballotti, Robert, additional, and Bahadoran, Philippe, additional

Published
2011
Full Text
View/download PDF

16. Childhood Acquired Epidermolysis Bullosa

Author

Lacour, Jean-Philippe, primary, Bernard, Philippe, additional, Rostain, Gilles, additional, Baechler-Sadoul, Elisabeth, additional, Pisani, Anne, additional, and Ortonne, Jean-Paul, additional

Published
1995
Full Text
View/download PDF

21. Perialar intertrigo in children and adolescents: A multicenter prospective study of 41 cases.

Author

Sanchez A, Mahe E, Miquel J, Abasq C, Phan A, Mazereeuw-Hautier J, Lemille J, Maruani A, Bonniaud B, Plantin P, Mallet S, Martin H, Hubiche T, Chiaverini C, and Lacour JP

Subjects
Adolescent, Child, Cohort Studies, Female, Humans, Male, Prospective Studies, Intertrigo diagnosis, Psoriasis diagnosis, Rosacea
Abstract

Background/objectives: We observed isolated cases of perialar intertrigo in children and teenagers that did not appear to correspond to any known clinical entity. The objective of this study was to describe the clinical features of this dermatosis and the clinical characteristics of the patients., Methods: We conducted a prospective, multicenter cohort study in France from August 2017 to November 2019. All the patients under 18 years of age with chronic perinasal intertrigo were included. A standardized questionnaire detailing the clinical characteristics of the patients and the description of the intertrigo. If possible, a Wood's lamp examination of the intertrigo was done., Results: Forty-one patients were included (25 boys and 16 girls, average age: 12.1 years). Intertrigo was bilateral in 38 patients (93%). The majority of patients had no symptoms (54%). Pruritus was present in 39% of cases. Orange red follicular fluorescence was present in the perialar region on Wood's light examination in 78% of cases with active fluorescence. The presumptive diagnoses suggested by the investigators were acne (24.4%), seborrheic dermatitis (19.5%), rosacea (9.8%), psoriasis (9.8%) and perioral dermatitis (7.3%). No diagnosis was proposed in 22% of the cases., Conclusions: We describe a previously undescribed clinical sign which is characterized by a chronic bilateral erythematous intertrigo located in the perialar region. It can be isolated or associated with various facial dermatoses., (© 2022 The Authors. Pediatric Dermatology published by Wiley Periodicals LLC.)

Published
2022
Full Text
View/download PDF

22. Switching biologics in children with psoriasis: Results from the BiPe cohort.

Author

Phan C, Beauchet A, Reguiai Z, Severino-Freire M, Mazereeuw-Hautier J, Bursztejn AC, Barbarot S, Hadj-Rabia S, Girard C, Phan A, Lacour JP, Lasek A, Abasq C, Brenaut E, Perrussel M, Droitcourt C, Mallet S, Piram M, Fougerousse AC, Barthélémy H, Balguérie X, and Mahé E

Subjects
Adalimumab adverse effects, Adolescent, Adult, Child, Etanercept adverse effects, Female, Humans, Retrospective Studies, Treatment Outcome, Ustekinumab therapeutic use, Young Adult, Biological Products adverse effects, Psoriasis drug therapy
Abstract

Background: There is currently little information on switching biologics in pediatric psoriasis., Objective: To evaluate the real-world clinical practice and safety of switching biologics in the "Biological Treatments for Pediatric Psoriasis" (BiPe) cohort., Methods: Data for all 134 patients included in the BiPe cohort were analyzed. A further evaluation of the subpopulation of patients who switched from a first-line biologic to a second-line biologic was then conducted. Drug survival rates were also compared between biologics given as first-line or second-line agents., Results: Overall, 29 patients (female: 55%; mean age: 16.6 ± 3.0 years) switched between two biologics. Etanercept (ETN) was the first-line biologic used in 23 patients: 16 (69.6%) switched to adalimumab (ADA) and seven (30.4%) to ustekinumab (UST). Six patients received first-line ADA and switched to UST. Loss of efficacy (62.1%), primary inefficacy (20.7%), and parental choice (6.9%) were the main reasons for switching biologics. One (3.4%) of the switches was performed because of adverse events or intolerance. For UST and ADA, the 18-month drug survival rate did not differ according to whether the agent was given as a first-line or second-line biologic (UST: P = .24; ADA: P = .68). No significant differences in drug survival rates were observed between the three different switches (ADA to UST, ETN to ADA, and ETN to UST)., Conclusion: Our study provided key insights into the real-life clinical practice of switching biologics in pediatric psoriasis patients. However, more information and guidance on switching biologics in pediatric psoriasis are needed to improve real-life practice and outcomes., (© 2021 Wiley Periodicals LLC.)

Published
2022
Full Text
View/download PDF

23. Papular, profuse, and precocious keratosis pilaris.

Author

Castela E, Chiaverini C, Boralevi F, Hugues R, and Lacour JP

Subjects
Child, Preschool, Darier Disease, Eyebrows abnormalities, Eyebrows pathology, Female, Folliculitis etiology, Folliculitis pathology, Humans, Infant, Keratosis complications, Male, Abnormalities, Multiple drug therapy, Abnormalities, Multiple pathology, Emollients therapeutic use, Keratolytic Agents therapeutic use, Keratosis drug therapy, Keratosis pathology
Abstract

Keratosis pilaris (KP) is a frequent and benign condition in children characterized by the presence of rough, follicular papules and varying degrees of erythema. Different variants have been described, including simple KP and red KP. Between September 2007 and October 2010, 11 children with profuse and precocious KP seen at the department of pediatric dermatology were included. They defined an underemphasized clinical variant of childhood KP: the papular, profuse, and precocious KP characterized by early age of onset (<18 mos), extensive involvement of the limbs and cheeks, and papular nature of lesions. No clinical association has been found. The main complication was episodes of folliculitis. Diagnosis was delayed for all patients. Treatment is difficult, but association between emollient and keratolytic agents can provide some help., (© 2011 Wiley Periodicals, Inc.)

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results